HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma.

AbstractPURPOSE:
To elucidate the efficacy of intensive induction and consolidation chemotherapy regimens (Study Group of Japan for Advanced Neuroblastoma [JANB] 85) for patients with advanced neuroblastoma aged 1 year or older.
PATIENT AND METHODS:
One hundred fifty-seven patients with newly diagnosed advanced neuroblastoma were entered into this study between January 1985 and December 1990. Eligible patients were 12 months old or older with stage III or IV disease. The patients first received six cyclic courses of intensive induction chemotherapy (designated regimen A1) consisting of cyclophosphamide (1,200 mg/m2), vincristine (1.5 mg/m2), tetrahydro-pyranyl Adriamycin (pirarubicin; 40 mg/m2), and cisplatin (90 mg/m2). The patients were further treated with three different consolidation protocols: 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosour ea, dacarbazine, and bone marrow transplantation.
RESULTS:
Overall survival rates for patients with stage III disease without reference to the consolidation protocols were 80.8%, 76.9%, and 66.3% at 2, 5, and 10 years, respectively. The overall survival rates for patients with stage IV disease were 58.8%, 34.4%, and 28.9% at 2, 5, and 10 years, respectively. There were no statistically significant differences between the three consolidation treatment groups. Patients who did not achieve complete remission (CR) with induction chemotherapy and surgery all died, suggesting that CR is essential for the cure of advanced neuroblastoma. The overall 5-year survival rate of the 24 patients with N-myc amplified stage III and IV disease was 33.3%, and the longest survival time of a relapse-free patient was 103 months.
CONCLUSION:
The intensive induction chemotherapy regimen used in this study may be of significant value in increasing the CR rate and survival for patients with N-myc amplified and nonamplified advanced neuroblastoma.
AuthorsM Kaneko, Y Tsuchida, J Uchino, T Takeda, M Iwafuchi, N Ohnuma, H Mugishima, J Yokoyama, H Nishihira, K Nakada, S Sasaki, T Sawada, K Kawa, N Nagahara, S Suita, S Sawaguchi
JournalJournal of pediatric hematology/oncology (J Pediatr Hematol Oncol) 1999 May-Jun Vol. 21 Issue 3 Pg. 190-7 ISSN: 1077-4114 [Print] UNITED STATES
PMID10363851 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Nimustine
  • Vincristine
  • Dacarbazine
  • Doxorubicin
  • Cyclophosphamide
  • pirarubicin
  • Cisplatin
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bone Marrow Transplantation
  • Child
  • Child, Preschool
  • Cisplatin (administration & dosage)
  • Cyclophosphamide (administration & dosage)
  • Dacarbazine (administration & dosage)
  • Doxorubicin (administration & dosage, analogs & derivatives)
  • Genes, myc
  • Humans
  • Infant
  • Neoplasm Staging
  • Neuroblastoma (drug therapy, genetics, pathology)
  • Nimustine (administration & dosage)
  • Remission Induction
  • Survival Analysis
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: